BiondVax Pharmaceuticals (NASDAQ:BVXV) Shares Pass Above Fifty Day Moving Average of $1.37

BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) shares crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $1.37 and traded as high as $1.37. BiondVax Pharmaceuticals shares last traded at $1.36, with a volume of 23,023 shares traded.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on shares of BiondVax Pharmaceuticals in a research note on Friday. They set a “hold” rating for the company.

BiondVax Pharmaceuticals Trading Up 3.8 %

The stock’s 50 day moving average price is $1.37 and its two-hundred day moving average price is $1.71. The firm has a market capitalization of $2.54 million, a PE ratio of -0.53 and a beta of 2.37.

BiondVax Pharmaceuticals (NASDAQ:BVXV) last released its earnings results on Friday, August 11th. The company reported ($1.11) EPS for the quarter. Analysts expect that BiondVax Pharmaceuticals Ltd. will post -0.01 earnings per share for the current year.

Institutional Trading of BiondVax Pharmaceuticals

An institutional investor recently raised its position in BiondVax Pharmaceuticals stock. Sabby Management LLC boosted its position in BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) by 47.8% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 325,974 shares of the company’s stock after acquiring an additional 105,412 shares during the period. BiondVax Pharmaceuticals comprises approximately 0.6% of Sabby Management LLC’s holdings, making the stock its 11th biggest holding. Sabby Management LLC owned 17.45% of BiondVax Pharmaceuticals worth $704,000 at the end of the most recent quarter. Institutional investors own 11.83% of the company’s stock.

BiondVax Pharmaceuticals Company Profile

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.